PMID- 27573547
OWN - NLM
STAT- MEDLINE
DCOM- 20170403
LR  - 20171116
IS  - 1791-2423 (Electronic)
IS  - 1019-6439 (Linking)
VI  - 49
IP  - 3
DP  - 2016 Sep
TI  - Suppression of MMP-9 and FAK expression by pomolic acid via blocking of 
      NF-kappaB/ERK/mTOR signaling pathways in growth factor-stimulated human breast cancer 
      cells.
PG  - 1230-40
LID - 10.3892/ijo.2016.3585 [doi]
AB  - The expression of matrix metalloproteinase-9 (MMP-9) and the phosphorylation of 
      focal adhesion kinase (FAK) have been implicated in the invasion, metastasis and 
      cell motility of cancer cells. It is considered that epidermal growth factor 
      (EGF) may increase cell motility, an event involved in cancer cell invasion and 
      metastasis. Pomolic acid (PA), an active triterpenoid from Euscaphis japonica, is 
      known to inhibit the proliferation of a variety of cancer cells, but the effect 
      of PA on the invasiveness of cancer cells is largely unknown. In this study, we 
      first determined the molecular mechanism by which PA inhibits the migratory and 
      invasive abilities of highly metastatic MDA-MB‑231 cells. Transwell invasion, 
      wound-healing assay and F-actin reorganization showed that PA significantly 
      inhibits the EGF-induced invasion, migration and cell motility by reducing 
      expression of MMP-9 and FAK phosphorylation. In particular, PA potently 
      suppressed the phosphorylation of nuclear factor (NF)-kappaB, extraceullar 
      signal-regulated kinase (ERK), phosphatidylinositol 3-kinase (PI3K)/Akt/mammalian 
      target of rapamycin (mTOR) signaling pathway. Furthermore, PA treatment inhibited 
      the DNA binding activity of NF-kappaB and activator protein (AP)-1, which is known to 
      mediate the expression of EGFR and MMP-9. These results suggest that PA may be a 
      potential therapeutic candidate for treatment of breast cancer metastasis.
FAU - Park, Ji-Hyun
AU  - Park JH
AD  - College of Pharmacy, Keimyung University, Daegu 42601, Republic of Korea.
FAU - Cho, Yoon Young
AU  - Cho YY
AD  - Department of Oncology/Hematology, Daegu Catholic University Medical Center, 
      Daegu 42472, Republic of Korea.
FAU - Yoon, Seong Woo
AU  - Yoon SW
AD  - Department of Korean Internal Medicine, Korean Medicine Cancer Center, Kyung Hee 
      University Hospital at Gangdong, Seoul 05278, Republic of Korea.
FAU - Park, Byoungduck
AU  - Park B
AD  - College of Pharmacy, Keimyung University, Daegu 42601, Republic of Korea.
LA  - eng
PT  - Journal Article
DEP - 20160629
PL  - Greece
TA  - Int J Oncol
JT  - International journal of oncology
JID - 9306042
RN  - 0 (Antineoplastic Agents, Phytogenic)
RN  - 0 (NF-kappa B)
RN  - 60HAB1ZK1T (pomolic acid)
RN  - 62229-50-9 (Epidermal Growth Factor)
RN  - 6SMK8R7TGJ (Oleanolic Acid)
RN  - EC 2.7.1.- (Phosphatidylinositol 3-Kinases)
RN  - EC 2.7.10.2 (Focal Adhesion Kinase 1)
RN  - EC 2.7.10.2 (PTK2 protein, human)
RN  - EC 3.4.24.35 (MMP9 protein, human)
RN  - EC 3.4.24.35 (Matrix Metalloproteinase 9)
SB  - IM
MH  - Antineoplastic Agents, Phytogenic/*pharmacology
MH  - Breast Neoplasms/drug therapy/*metabolism
MH  - Cell Line, Tumor
MH  - Cell Movement/drug effects
MH  - Epidermal Growth Factor/pharmacology
MH  - Female
MH  - Focal Adhesion Kinase 1/*metabolism
MH  - Gene Expression Regulation, Neoplastic/drug effects
MH  - Humans
MH  - MAP Kinase Signaling System/drug effects
MH  - Matrix Metalloproteinase 9/*metabolism
MH  - NF-kappa B/metabolism
MH  - Neoplasm Invasiveness
MH  - Oleanolic Acid/*analogs & derivatives/pharmacology
MH  - Phosphatidylinositol 3-Kinases/metabolism
MH  - Phosphorylation/drug effects
EDAT- 2016/08/31 06:00
MHDA- 2017/04/04 06:00
CRDT- 2016/08/31 06:00
PHST- 2016/04/22 00:00 [received]
PHST- 2016/06/14 00:00 [accepted]
PHST- 2016/08/31 06:00 [entrez]
PHST- 2016/08/31 06:00 [pubmed]
PHST- 2017/04/04 06:00 [medline]
AID - 10.3892/ijo.2016.3585 [doi]
PST - ppublish
SO  - Int J Oncol. 2016 Sep;49(3):1230-40. doi: 10.3892/ijo.2016.3585. Epub 2016 Jun 
      29.